A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase Ia Study in Chinese Healthy Adult Subjects to Investigate the Safety, Tolerability and Pharmacokinetic of TG103
Latest Information Update: 17 Sep 2021
At a glance
- Drugs GX G6 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 22 Nov 2020 Status changed from recruiting to completed.
- 19 Jun 2019 New trial record